Based on these findings, we propose that the NF-κB p65–Sorcin–ChREBP cytosolic complex to be a potential site for pharmacological interventions as an effective therapy for reducing high carbohydrate diet–induced fatty liver disease. This evidence concerns the gene MLXIPL and fatty liver disease.